EMA Authorised: Evkeeza (Evinacumab) — Ultragenyx Germany GmbH

View source ↗

Summary

EMA authorised Evkeeza (evinacumab) for hypercholesterolemia under Ultragenyx Germany GmbH, decision dated 08/07/2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Evkeeza (evinacumab)

Snippet

Status: Authorised. Therapeutic area: Hypercholesterolemia. MAH: Ultragenyx Germany GmbH. Decision date: 08/07/2026